MYC rearrangement, a disease-initiating event in Burkitt lymphoma (BL), can be observed in approximately 10% of de novo DLBCL and correlates with a poorer outcome [3–7]. This evidence concerns the gene MYC and diffuse large B-cell lymphoma.